ABSTRACT
Cardiac-related adverse events are becoming well-recognized and are common complications for cancer patients during treatment and throughout survivorship. Cardiac manifestations such as arrhythmias, hypertension, heart failure, and myocardial infarction are major causes of morbidity and mortality. As such, there have been significant advancements in the management of these patients to reduce the incidence of cardiotoxicity from various cancer treatments.
This chapter will provide a brief overview of the evolution of cancer treatment as it pertains to mitigating the effects of cardiotoxic anticancer therapies. Topics include: chemotherapeutics, monoclonal antibodies, small molecules, immunotherapy, radiation therapy, and supportive medications in cardiology. Emerging cardiac monitoring methodologies, cardioprotective treatments, and cardio-oncology from a multidisciplinary perspective will also be discussed.
